A.R.T. Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

A.R.T. Advisors’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-29,813	Closed	-$1.13M	–	1777
2018 Q3	$1.13M	Sell	29,813 -27,500	-48%	-$1.22M	0.05%	530
2018 Q2	$2.59M	Buy	57,313 +21,100	+58%	+$961K	0.11%	277
2018 Q1	$1.75M	Buy	36,213 +27,400	+311%	+$1.53M	0.07%	443
2017 Q4	$346K	Sell	8,813 -82,000	-90%	-$3.06M	0.02%	1021
2017 Q3	$2.82M	Sell	90,813 -9,000	-9%	-$253K	0.14%	183
2017 Q2	$2.73M	Buy	99,813 +83,800	+523%	+$2.49M	0.14%	177
2017 Q1	$590K	Buy	+16,013	New	+$403K	0.03%	754
2016 Q3	–	Sell	-63,180	Closed	-$1.05M	–	1290
2016 Q2	$1.05M	Buy	63,180 +6,780	+12%	+$137K	0.05%	528
2016 Q1	$894K	Buy	56,400 +41,600	+281%	+$739K	0.04%	631
2015 Q4	$478K	Buy	+14,800	New	+$641K	0.02%	883

Other funds holding GBT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

A.R.T. Advisors's GBT Position: Q4 2018 in Review

A.R.T. Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2018, closing a stake of 29,813 shares — an estimated $1.13M sold.

A.R.T. Advisors first reported a position in GBT in Q4 2015 and held it in 10 quarters. The position peaked at $2.82M in Q3 2017. 190 funds tracked by Wall St. Rank hold GBT as of Q4 2018.

A.R.T. Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
A.R.T. Advisors sold 29,813 Global Blood Therapeutics, Inc. shares in Q4 2018, an estimated $1.13M.
A.R.T. Advisors first reported a position in Global Blood Therapeutics, Inc. in Q4 2015 and held it in 10 quarters.
A.R.T. Advisors's Global Blood Therapeutics, Inc. position peaked at $2.82M in Q3 2017.
190 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2018.

Based on A.R.T. Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.